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Anti-Ge2: further evidence for lack of clinical 
significance
D. Karunasiri, F. Lowder, N. Ostrzega, and D. Goldfinger
Anti-Ge2 may be immune or naturally occurring, and it reacts 
with an antigen on glycophorin D. Ge2 is encoded by a gene, 
GYPC, which is located on the long arm of chromosome 2. 
Anti-Ge2 is usually an immunoglobulin G (IgG) antibody. 
In the available literature, we have not been able to find any 
reported cases of proven acute hemolytic transfusion reactions 
caused by anti-Ge2. We present the case of a 67-year-old man 
with metastatic pancreatic carcinoma who had symptomatic 
anemia and a hemoglobin concentration of 6.3 g/dL. During 
pretransfusion testing, anti-Ge2 was identified in his serum. 
Only a single unit of compatible, Ge:–2 frozen red blood cells 
(RBCs) could be provided by the blood supplier. A second 
unit of crossmatched, least-incompatible, leukocyte-reduced 
RBCs, presumably Ge:2, was also transfused. The transfusion 
was completed without incident, and the patient’s hemoglobin 
concentration rose appropriately. Posttransfusion values for 
haptoglobin, lactate dehydrogenase, and urine hemoglobin were 
within normal limits. A monocyte monolayer assay performed on 
this anti-Ge2 supports the data that antibodies of this specificity 
do not cause hemolysis. The clinical and laboratory data obtained 
in our patient clearly indicated that no hemolysis of transfused 
RBCs occurred during and for 24 hours after transfusion. We 
believe that this report adds to a limited experience with anti-
Ge2 and provides further evidence for concluding that, in all 
likelihood, this is not a clinically important RBC antibody. The 
risk of transfusing apparently “incompatible” (Ge:2) RBCs seems 
remote and should allow for timely administration of RBCs when 
treating patients with serious anemia. Immunohematology 
2014;30:156–157.
The Gerbich blood group system is composed of 11 
antigens that are expressed on glycophorin C (GPC) and 
glycophorin D (GPD).1 Both are encoded by a single gene, 
GYPC, which is located on the long arm of chromosome 2. 
Gerbich antigens are inherited as autosomal-dominant traits. 
Of the 11 antigens in the Gerbich system, 6 of them are high-
prevalence antigens, including Ge:2. Anti-Ge2 may be immune 
or naturally occurring, and it reacts with an antigen on GPD. 
Anti-Ge2 is usually an immunoglobulin G (IgG) antibody.
In the available literature, we have not been able to find 
any reported cases of proven acute hemolytic transfusion 
reactions caused by anti-Ge2. Yet the presence of this antibody 
in patient plasma is cause for concern when transfusing 
incompatible Ge:2 red blood cells (RBCs). We found two 
reports of successful transfusion of Ge:2 RBCs in patients 
with strongly reactive anti-Ge2.2,3 We now report another 
case of successful transfusion of Ge:2 RBCs in a patient with 
demonstrable anti-Ge2.
Case Report
A 67-year-old man with metastatic pancreatic carcinoma 
and biliary obstruction was admitted to the Olive View 
UCLA Medical Center with symptomatic anemia and a 
hemoglobin concentration of 6.3 g/dL. His blood group was 
O Rh (D) positive. During pretransfusion testing, an antibody 
of undetermined specificity was detected (1+ to 2+) by the 
polyethylene glycol indirect antiglobulin test. A blood sample 
was sent to a reference laboratory for further testing, and anti-
Ge2 was identified. Only a single unit of compatible, Ge:–2 
frozen RBCs could be provided by the blood supplier.
We transfused the compatible unit of RBCs without 
incident. A second unit of crossmatched, least-incompatible, 
leukocyte-reduced RBCs, presumably Ge:2, was then 
transfused. We advised the clinician to transfuse this unit 
slowly and monitor the patient closely for any adverse effects. 
The transfusion was completed without incident, and the 
patient’s hemoglobin concentration rose appropriately. Table 
1 shows the values for laboratory tests performed before 
and 1 day after transfusion. Values for haptoglobin, lactate 
dehydrogenase, and urine hemoglobin were within normal 
limits. Serum bilirubin was elevated before transfusion and 
could not be used as a measure of hemolysis.
A monocyte monolayer assay was performed by the 
American Red Cross Reference Laboratory as previously 
described.4 Reactivity greater than 5 percent can be associated 
with overt transfusion reactions in patients who receive 
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98–192 U/L) Urine hemoglobin
Before 
transfusion
6.3 g/dL Not available Not available Not available
1 day after 
transfusion
9.2 g/dL 255 mg/dL 179 U/L Negative
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incompatible RBCs. Our patient demonstrated less than 1 
percent reactivity, indicating that this anti-Ge2 would not be 
expected to cause acute hemolysis of transfused Ge:2 RBCs.
Discussion
Antibodies to high-prevalence antigens pose an especially 
difficult problem regarding patient management. The delays 
encountered in obtaining compatible, antigen-negative units 
of RBCs can place patients who require timely transfusion 
for severe anemia in real jeopardy. Therefore, knowledge of 
whether particular antibody specificity is clinically significant 
can be of huge importance in guiding patient care. However, 
the rarity of these cases makes obtaining adequate data 
for evidence-based decisions a challenge. The clinical and 
laboratory data obtained in our patient clearly indicate that 
no hemolysis of transfused RBCs occurred during and for 24 
hours after transfusion.
We believe that this report adds to a limited experience 
with anti-Ge2 and provides the basis for concluding that, in 
all likelihood, this is not a clinically important RBC antibody. 
The risk of a patient experiencing an adverse reaction after 
transfusion of apparently “incompatible” Ge:2 RBCs seems 
remote, and this information should allow for more timely 
administration of RBCs when treating patients with serious 
anemia.
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